Maze Therapeutics, Inc.

MAZE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
Operating Activities
Net Income$52-$100-$115
Dep. & Amort.$3$4$4
Deferred Tax$0$0$0
Stock-Based Comp.$10$9$7
Change in WC-$2-$6-$3
Other Non-Cash$12$7$8
Operating Cash Flow$76-$87-$99
Investing Activities
PP&E Inv.-$1-$0-$2
Net Acquisitions$0$0-$1
Inv. Purchases$0$0$0
Inv. Sales/Matur.$0$0$0
Other Inv. Act.$0$0$0
Investing Cash Flow-$1-$0-$3
Financing Activities
Debt Repay.$24$16$0
Stock Issued$68$0$2
Stock Repurch.$0$0$0
Dividends Paid$0$0$0
Other Fin. Act.$0$0$0
Financing Cash Flow$93$16$2
Forex Effect$0$0$0
Net Chg. in Cash$168-$71-$101
Supplemental Information
Beg. Cash$30$101$202
End Cash$198$30$101
Free Cash Flow$75-$87-$101
Maze Therapeutics, Inc. (MAZE) Financial Statements & Key Stats | AlphaPilot